HeartFlow has raised $531.7M across 1 funding round, plus 1 undated round. The company is valued at $1.6B.
Heartflow is backed by investors including Bain Capital Life Sciences and Baillie Gifford, funding that carried the company from a venture-backed startup to its 2025 Nasdaq listing under the ticker HTFL.
1 funding round, the latest highlighted.
HeartFlow was founded in 2007, United States.
No date is disclosed for this round.
Listed company.
1 dated round, newest first.
Baillie GiffordCCapricorn Investment GroupHHayfin Capital ManagementHHealthCorMMartis CapitalUUSVP
Wellington ManagementLead investors for each round are in the funding timeline.
The closest medical ai / cardiac diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. HeartFlow is listed on NASDAQ as HFLO.
The last valuation is $1.6B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
